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Indolent lymphomas have recently been the object of numerous studies, which have focused on new aspects
relevant both for the better comprehension of their histogenesis and the identification of new therapeutic strat-
egies. As marginal-zone lymphoma (MZL) represents the category of indolent lymphomas that has obtained
more benefit from such an approach, the authors focused on the most recent achievements and not yet solved
controversies in this area. In spite of their postulated common derivation, the three categories of MZL of the
WHO Classification appear dissimilar. In fact, they show significant molecular differences among them as well
as a certain heterogeneity within each group. By no means, there is a cogent need of more refined tools to revise
these neoplasms and to produce a more rational grouping. The recent identification of the IRTA gene family cor-
responding to IG-like receptors differentially expressed in B-cells might contribute to their better understanding.
Key words: extranodal marginal zone lymphoma, indolent lymphoma, lymphoma classification, nodal 
marginal zone lymphoma, primary splenic marginal zone lymphoma
Introduction
In 1994, the members of the International Lymphoma Study
Group (ILSG) proposed the Revised European American Lym-
phoma (REAL) classification [1], aiming to overcome the differ-
ent approaches (e.g. the Kiel classification [2, 3] and working
formulation [4]) employed in Europe and the USA, which
hampered the comparison among clinico-pathological trials. The
proposal of the REAL classification was followed by a validation
study, carried out by pathologists external to the ILSG and based
on a series of cases collected worldwide, which showed that the
ILSG scheme was superior to both the Kiel classification and
working formulation in terms of interpersonal and intrapersonal
reproducibility [5]. More recently, the World Health Organisation
(WHO) has adopted the REAL classification as a model for
the categorisation of all the tumours of the lymphoid and haema-
topoietic tissues [6].
The REAL/WHO classification [1, 6] consists of a list of dis-
tinct entities, which are defined by the amalgamation of morph-
ology, phenotype, genotype and clinical findings, and can be
updated on the basis of new evidence emerging from the literature.
Conversely to previous schemes, the REAL/WHO classification
does not provide grades of malignancy, as the clinical behaviour
and response to therapy are not influenced by the cell size and
number of mitotic figures, as postulated in the Kiel classification
and working formulation, but depend on the category the tumour
belongs to and within each category on a series of biological
mechanisms, which are at work differently in each individual
patient. On one hand, this explains the artificiality of certain dis-
tinctions of the past, such as the ones between low- and high-grade
peripheral T-cell lymphomas, all types of T-cell tumour showing a
poor prognosis with the exception of mycosis fungoides and
ALK-positive anaplastic large cell lymphoma. On the other hand,
such an approach has favoured research activity to better define
the risk factors within each lymphoma category, that has found its
cutting edge in the tissue micro-array and gene expression profil-
ing techniques.
In 1995, Dan Longo [7] proposed the usage of some terms such
as indolent, aggressive and very aggressive lymphoma, which refer
to the natural history of the disease irrespective of its response to
therapy. Although they are not included in the REAL/WHO
classification, these terms are commonly used in daily practice. In
particular, the label ‘indolent’ lymphoma applies to lymphoid
tumours with a survival measurable in years, irrespective of
whether or not any therapy is given. These lymphoproliferative
disorders have variable clinical presentations. Some are con-
stantly systemic diseases, often with leukaemic manifestations.
Others have an extranodal primary presentation and can remain
localised for long periods, even in the absence of any therapy. Yet
others correspond to tumours with nodal presentation, which can
have widespread immune system involvement at the time of diag-
nosis. This has led to the basic distinction of three fundamental
subtypes of indolent lymphoma: disseminated leukaemias/lymph-
omas, extranodal forms and nodal ones (Table 1). Interestingly, all
these neoplasms are derived from the B-cell system, except T
large granular lymphocyte leukaemia. In spite of the fact that they
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correspond to entities widely acknowledged in the literature, most
of them have recently been the object of challenging molecular
studies, which have focused on new aspects relevant both for the
better understanding of their histogenesis and the identification of
new therapeutic strategies. As marginal zone lymphoma (MZL)
represents the category of ‘indolent lymphomas’ that has obtained
most benefit from such an approach [8], this review focuses on the
most recent achievements and as yet unsolved controversies in
this area.
Marginal zone lymphoma
The REAL classification [1] listed three types of MZL: extra-
nodal, nodal and primary splenic. The former was regarded as an
accepted entity, while the latter two were considered as pro-
visional entities. The WHO classification [6] listed the three forms
as accepted entities. However, there are still many uncertainties as
to whether or not they represent a homogeneous group of tumours.
Normal marginal zone B-cell compartment
The marginal zone (MZ) corresponds to the outer part of second-
ary follicles (for a comprehensive review of the topic see Kurtin
[9]). It is well developed and easily recognisable in the spleen,
intra-abdominal lymph nodes and mucosa-associated lymphoid
tissue (MALT). The latter corresponds to Peyer patches physio-
logically present at birth (native MALT) or develops during life at
different anatomic sites, including the stomach, thyroid, salivary
gland, lung and skin, because of a chronic inflammation sustained
by an infective agent and/or an auto-immune condition (acquired
MALT). Most MZ cells express CD19 and CD20 and have the
phenotypic profile of memory B-cells. Thus, they are strongly
positive for immunoglobulin (Ig) of the M class, IgG or IgA, only
a small subpopulation exhibiting weak IgD staining. They also
express CD21, CD27 and Bcl-2 protein, but are negative for CD5,
CD10, CD23, CD43, CD75 and Ki-B3 (an antibody that recog-
nises a glycosilation-independent epitope of CD45RA, expressed
by B-lymphocytes that are immunocompetent, but have not yet
responded to antigens). A subset of splenic MZ cells, however,
shares phenotypic features with mantle B-elements by showing
positivity for IgM, IgD and Ki-B3, and negativity for CD21 and
CD27. On molecular grounds, micro-dissection PCR studies have
shown that most splenic MZ B-cells contain point mutations of
the Ig genes at frequencies found in post-follicular memory
B-elements. However, a small subset of the same MZ B-cells dis-
plays a low load of Ig gene point mutations, as usually found in
mantle B-cells. Therefore, although belonging to the same ana-
tomic compartment, splenic MZ B-elements do show a certain
phenotypic and molecular variability, the vast majority of them
being likely part of the recirculating memory B-cell pool. Interest-
ingly, splenic MZ B-cells can bind polysaccharide antigens with
one of two results, depending on the follicle microenvironment.
First, they can migrate into the germinal centres (GC) and present
the antigen to GC B-cells. If follicular dendritic cells have surface
Ig that binds to the presented antigen, they proliferate and give
raise to the GC cell reaction. Second, antigen in association with
cytokines released by T-cells can rapidly induce differentiation of
MZ B-cells into plasma cells, which in turn synthesise and release
antigen-specific Ig.
It has repeatedly been reported in the literature that ‘mono-
cytoid B-cells’ belong to the MZ B-cell compartment. These
elements are characterised by medium size, distinct cellular con-
tours, clear cytoplasm, variably shaped nuclei, and inconspicuous
nucleoli [10]. They are commonly seen in lymph nodes during the
course of different types of lymphadenitis and most often form
clusters within or around sinuses and in the interfollicular areas,
although they occasionally surround benign follicles to produce a
marginal zone pattern [11]. In spite of the common belief that they
belong to the MZ cell pool, which is probably based on their usual
IgG expression, no firm proof has been provided yet that ‘mono-
cytoid B-cells’ have post-GC cell derivation [12]. In fact, immuno-
phenotypic analysis reveals positivity for Ki-B3/CD45RA and
CD75 and negativity for CD21 and CD27 [9]. In addition, molecu-
lar studies display regular lack of somatic mutations of IgVH
genes as observed in naïve B-elements.
Extranodal marginal zone lymphoma
Extranodal MZL is thought to stem from MZ cells of MALT [13–
17]. In the REAL/WHO classification [1, 6], by definition the
term extranodal MZL is restricted to tumours consisting of small
elements provided with centrocyte-like or monocytoid morph-
ology and associated or not with plasmacytoid differentiation,
which resemble normal MALT MZ cells and share with them
phenotypic and molecular characteristics, including the IRTA-1
gene expression (B. Falini, personal communication). According
to the original description, these neoplasms are also called MALT
lymphomas.
Because of its high prevalence and clinical relevance, MZ/
MALT lymphoma of the stomach has been the object of recent
research, which led to better understanding of its characteristics,
including lympho-epithelial lesion formation, multicentricity,
pathogenetic relationships to Helicobacter pylori (HP) infection
Table 1. List of indolent lymphomas
MALT, mucosa-associated lymphoid tissue.
Disseminated lymphomas/leukaemias
B-cell chronic lymphocytic leukaemia
Lymphoplasmacytic lymphoma
Hairy cell leukaemia
Splenic marginal zone B-cell lymphoma (±villous lymphocytes)
Plasma cell myeloma/plasmacytoma
T large granular lymphocyte leukaemia
Extranodal lymphomas
Extranodal marginal zone B-cell lymphoma of MALT type
Nodal lymphomas
Small lymphocytic lymphoma
Follicular lymphoma
Nodal marginal zone B-cell lymphoma (±monocytoid B-cells)
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and susceptibility to antibiotics [17, 18]. Following preliminary
reports which suggested that most gastric MZLs could regress
following HP eradication [19–21], it is now clear that this event
occurs in only 50–55% of cases [17, 18]. Interestingly, besides the
regression of a gastric tumour, antibiotic therapy may at times
produce disappearance of a contemporary extranodal MZL at
another anatomic site: in one of these cases, a clonal relationship
between the two tumours has been documented in the literature
[22]. Ultrasound endoscopy has shown that regression is unlikely
in cases with infiltration of the muscolaris propria or entire gastric
wall, as well as in patients with peri-gastric lymph node involve-
ment [23].
Cytogenetic and molecular studies have recently shown that
extranodal MZL is characterised by the occurrence of different
chromosomal aberrations, which influence its invasive potential
and possible response to therapy. In particular, three chromo-
somal aberrations have been detected, t(1;14), t(11;18) and
t(14;18), which are possibly involved in the process of lymphoma-
genesis and affect the course of the disease [24]. t(1;14)(p22;q32)
is exceedingly rare and causes transfer of the BCL10 gene close to
the Ig enhancer on chromosome 14, thus causing overexpression
of the corresponding product that accumulates at the nuclear level,
and may be provided with oncogenic activity [25–28]. t(14;18)
(q21;q21) is detected in 30–35% of gastric MZLs and produces
the formation of the fusion gene API2-MALT1 [29–39]. Interest-
ingly, this aberration, which can be reliably detected in routine
material by appropriate PCR studies [32, 37], is also associated
with BCL10 protein accumulation within the nucleus of neo-
plastic cells [25, 26, 28, 31, 33]. The explanation of how the same
phenomenon can be pursued by seemingly unrelated transloca-
tions lays in the observation that under physiological conditions
BCL10 and MALT1 products form a strong and specific complex.
In particular, BCL10 mediates the oligomerisation of the MALT1
caspase-like domain with subsequent activation of the IKK com-
plex through an unknown mechanism, setting in motion a cascade
of events leading to NF-κB induction [26, 33]. Furthermore, the
API2-MALT1 fusion protein itself seems to strongly activate
NF-κB and to show dependence upon the same downstream sig-
nalling pathway [26, 33]. Thus, both the BCL10.MALT1 complex
and API2-MALT1 fusion protein might activate a common route
that originates with the oligomerisation-dependent activation of
the MALT1 caspase-like domain and leads to resistance to anti-
biotic therapy [30, 37]. Notably, besides antibiotic-resistance,
t(11;18) is characterised by a higher potential of local infiltration
and distance spread, as well as by the lack of both other chromo-
somal abnormalities and progression to a more aggressive tumour
[29, 31, 35, 36]. Epidemiological studies have recently shown
that the translocation is even more frequent in the lung than in
the stomach [34, 39] and is found also in approximately one-half
of the rare examples of gastric HP-negative MZL [38], thus fur-
ther supporting the concept that tumours carrying t(11;18) do not
need HP stimulation for their growth and maintenance. t(14;18)
(q32;q21) has been the subject of much debate in the literature. In
fact, some authors thought that the translocation at times found in
extranodal MZLs could correspond to the one typically found in
follicular lymphoma (FL) and involving the BCL2 gene [1, 6]. In
reality, the t(14;18) of MZLs does not affect BCL2, but does affect
MALT1 by possibly following the same pathogenetic pathway as
t(1;14) and t(11;18) [40, 41]. According to the few data in the
literature, the translocation involving the Ig enhancer and MALT1
gene seems to be more frequent at anatomic sites other than the
gastrointestinal tract and, like t(1;14), to occur either as the sole
genetic abnormality or in conjunction with trisomy 3 and/or 18
[40]. It should always be distinguished from the translocation
involving the BCL2 gene by FISH and/or PCR analysis, also in the
light of the fact that FL may at times show prominent MZ differen-
tiation [42–45], thus blurring the morphological borders between
the two tumours. Features of MZ differentiation may also occur in
mantle cell lymphoma (MCL) [46]: under these circumstances,
the detection of t(11;14) and cyclin D1 overexpression along with
the lack of t(1;14), t(11;18) or t(14;18) does allow firm distinction
of this aggressive neoplasm from MZL.
Besides chromosomal translocations, two other issues have
gained attention in the field of MZLs: one of these pertains all
tumours irrespective of their primary site, while the other is
strictly related to gastric forms. In particular, the former issue
refers to the onset of a large B-cell lymphoma at an anatomic site
containing native or acquired MALT. Several authors have named
this tumour ‘high-grade MZ/MALT lymphoma’. The latter term
is not included in the REAL/WHO classification, because: the
label ‘MALT’ lymphoma is by definition restricted to neoplasms
showing small cell size and derivation from MALT MZ elements;
there is no evidence that a large B-cell lymphoma occurring de
novo at a MALT site is derived from MZ cells; and the clonal
relationship between a MZL and a large B-cell neoplasm simultan-
eously detected in the same organ should be proven molecularly,
as the latter can represent the blastic phase of the former, but might
also develop as a second unrelated neoplasm [1, 6]. In the few
cases in which a clonal progression from indolent to aggressive
lymphoma has been proven, a loss of expression of α4β7 integrin
and L-selectin has been recorded and supposed to take part in the
transforming event [47]. The other issue deals with the response to
antibiotic therapy and follow-up of patients with gastric MZL and
HP infection. First, morphology represents the most effective tool
to assess lymphoma regression, as PCR studies can show a mono-
clonal signal even years following therapy in the absence of any
sign of disease relapse [48–52]. Second, the monitoring of these
patients should be performed according to clear-cut guidelines
such as the ones proposed by the IELSG: the first biopsy should be
performed 1 month after the end of antibiotic treatment to assess
HP eradication, a second exam should be carried out 3 months
later by taking multiple samples from the area where the diagnosis
of lymphoma was originally made and at distance sites, in order to
evaluate the tumour response [52]. Each sample should be histo-
logically analysed at different levels to be sure that foci of the
disease are not neglected. At present, microscopic examination is
carried out according to the so-called Wotherspoon’s score [53].
However, there are several attempts underway to propose a moni-
toring approach more practical and reproducible than the one
described originally by Wotherspoon (A. Wotherspoon and C.
Copie-Bergmann, personal communication). In principle, in case
of no response to eradicating therapy, the bioptic material should
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be analysed on molecular grounds in order to check the possible
occurrence of chromosomal aberrations, which prevent the suc-
cessful application of antibiotics, thus leading to different options
(such as chemotherapy, surgery, radiotherapy and/or immuno-
therapy). On the other hand, cases which do show a significant
improvement after antibiotic therapy should be studied periodi-
cally over an indefinite period in order to evaluate the mainten-
ance of disease remission or possible lymphomatous relapse or
progression.
Nodal marginal zone lymphoma
In the WHO classification, nodal marginal zone lymphoma
(NMZL) is defined as a primary nodal B-cell neoplasm that mor-
phologically resembles lymph nodes involved by MZ lymphoma
of the extranodal or splenic type, but without evidence of extra-
nodal or splenic disease. According to this statement, one should
conclude that the terms extranodal, nodal and splenic MZL refer
to different clinical presentations of the same disease and the diag-
nosis of NMZL is based on the exclusion of a primary extranodal
or splenic tumour [6]. Several reports have underlined that there
are instead significant differences among the three neoplasms.
On clinical grounds, NMZL is more aggressive than the extra-
nodal and splenic forms [54–56]. For example, it shows a higher
incidence of advanced stage disease and lower 5-year overall and
disease-free survival [54, 55]. In addition, 10–20% of cases tend
to transform into a diffuse large B-cell lymphoma (DLBCL) [55].
At light microscopy, although centrocyte-like morphology can at
times be observed, most cases display a distinct ‘monocytoid’
appearance [1, 6, 55]. Because of this, the tumour was originally
termed ‘monocytoid B-cell lymphoma’ [55]. Accordingly, pheno-
typic analysis reveals common expression of Ki-B3/CD45RA and
CD75 and negativity for CD21 and CD27, thus differentiating the
nodal form from the splenic and extranodal forms [9]. Molecular
studies further strengthen the existence of significant differences
among the three tumours. First, t(11;18) has never been detected
in NMZL [34]. Second, the analysis of IgVH gene clearly shows
that some NMZLs carry somatic mutations, while others do not,
thus suggesting derivation from post-GC and virgin B-cells, respect-
ively [56, 57]. By contrast, the occurrence of ongoing mutations
represents a more controversial issue, as this might reflect the
inclusion of FLs with MZ differentiation within this category [57].
Interestingly, among mutated cases the usage of specific IgVH
gene segments seems to occur frequently and to discriminate
between hepatitis C virus (HCV)-positive and -negative patients
[58]. In the former, there is preferential usage of a VH1-69 seg-
ment with similar CDR3s, thus suggesting the presence of a
common antigen, probably a HCV antigen epitope, involved in
B-cell selection, while in the latter the use of a VH4-34 segment
might be related to the role of yet unknown B-cell super-
antigen(s) in the selection of tumour B-cell precursors. Finally,
none of the translocations characteristically recorded in SMZL,
e.g. del(7q), del(13q14) and del(10)(q22,q24), has so far been
detected in NMZL, thus further challenging the concept that the
three forms of MZL included in the WHO classification share a
common histogenesis [59, 60].
Splenic marginal zone lymphoma
Splenic marginal zone lymphoma (SMZL) has been the object of
numerous reports in the literature. It is generally characterised by
splenomegaly and leukaemic spread, although at times cases with
disseminated disease or exclusively leukaemic presentation have
been described [56]. In about half of cases, circulating neoplastic
cells display cytoplasmic villous projections [1, 6, 56], which
justify the term ‘splenic lymphoma with villous lymphocytes’
(SLVL) used in former studies [61]. Infiltration of the bone
marrow, which is recorded in most if not all patients, has been
claimed to be limited to the sinuses: however, this finding is
neither specific nor pathognomonic [56, 62, 63]. In fact, it can
occur in other types of malignant lymphoma and in SMZL it does
not represent the only type of bone marrow involvement, nodular
and/or interstitial components being frequently encountered. No
consensus has been achieved yet on the optimal therapeutic
approach. With only a few exceptions [64], authors agree on the
fact that subjects who underwent splenectomy fare better, thus
suggesting that splenectomy may be the first-line treatment choice
[65–68]. According to reported data, it can be delayed until the
occurrence of symptoms or cytopenia and seems to be per se suf-
ficient for correcting cytopenic manifestations, improving quality
of life and increasing survival (with median values of between 9
and 13 years) [56, 68]. The utility of alternative or complementary
approaches, such as chemotherapy, radiotherapy or the employ-
ment of humanised monoclonal antibodies targeted against B-cell-
associated antigens, should be clarified in prospective trials [69].
On practical grounds, several adverse prognostic predictors have
been quoted in the literature, including haemolytic anaemia,
immune thrombocytopenia, M-component in the serum, elevated
β2-microglobulin level, leucocyte count >20 000/µl, lymphocytes
>9000/µl, and p53 overexpression by neoplastic cells [56, 65–68].
Progression to DLBCL has been recorded in about 10% of
patients [70].
The analysis of a large series of cases has recently shown that
some tumours diagnosed as SMZL express CD5 and cyclin D1
and carry t(11;14) [56]. It is still unclear whether these cases
represent examples of mantle-cell lymphoma with marginal zone
differentiation. We have collected three neoplams with these
phenotypic and cytogenetic characteristics that showed the typical
morphology of SMZL (unpublished observation): they consisted
of medium-sized elements with clear cytoplasm and oval or
kidney-shaped nuclei, which grew around Malpighi’s corpuscle
with discrete diffusion through the splenic sinuses. The patients
had villous circulating lymphocytes and bone marrow sinusoidal
infiltration in the absence of other organ involvement. They all
underwent splenectomy and did not receive further therapies. Two
to 3 years after diagnosis, the patients are alive and well without
signs of disease progression. The collection of further such cases
is mandatory to assess which category of malignant lymphoma
they belong to.
Cytogenetics and molecular studies have shown that SMZL is a
heterogeneous tumour [56, 59, 60, 71]. In particular, Solé et al.
have proposed the distinction of SMZLs into two subtypes, one
with gain of 3q and the other with loss of 7q [60]. IgVH gene
analysis has revealed that some cases, in keeping with the usual
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strong expression of IgM and IgD in SMZL, reveal unmutated
genes, thus suggesting a naïve B-cell derivation [71, 72]. In other
cases, however, a significant number of somatic mutations is
detected as usually found in post-GC B-cells [71–74]. In one
instance, the switch from unmutated to hypermutated elements
was recorded within the same clone [75]: this suggests that the
tissue microenvironment can influence the tumour and raises the
question of a role for antigen in driving tumour growth. The latter
point is strengthened by the observation that the use of VH gene
segment in mutated cases seems to be non-random, the repetitive
usage of V1-2, V1-69 and V3-34 having been recorded [71, 72].
Interestingly, as in some NMZLs, the preferential use of VH gene
segment(s) might correlate with HCV infection, a fact which can
explain possible tumour regression following HCV eradication
[69].
Future perspectives
According to the above-mentioned data, the three types of MZL
quoted in the WHO classification [6] display significant differ-
ences among them as well as certain heterogeneity within each
category. There is a cogent need for a more refined tool to revise
this group of lymphoid neoplasms and produce a more rationale
grouping. The recent identification of the new IRTA gene family
corresponding to Ig-like receptors differentially expressed in
B-cells might contribute to the better understanding of MZLs
[76, 77]. In particular, IRTA1 is characteristic of MZ B-cells,
IRTA2 and IRTA3 are found in the GC light zone and interepi-
thelial and interfollicular regions and IRTA4 and IRTA5 are pre-
dominantly expressed in the mantle zone [76]. Molecular studies
based on single-cell or micro-dissection PCR as well as on the
availability of specific monoclonal antibodies, which is reason-
ably expected (B. Falini, personal communication), might clarify
which tumours merit the histogenetic label ‘marginal zone lymph-
oma’ and which do not. In the meantime, the controversies on the
nodal and splenic forms of MZL should be considered to be far
from their definitive solution.
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Note added in proof
After the acceptance of the present paper, Falini et al. published on
the first application of anti-IRTA1 specific antibodies to the
analysis of normal lymphoid tissues (Falini B, Tiacci E, Pucciarini
A et al. Expression of the IRTA1 receptor identifies intraepithelial
and subepithelial marginal zone B cells of the mucosa-associated
lymphoid tissue (MALT). Blood 2003; 102: 3684–3692). IRTA1
was selectively expressed by a B-cell population located under-
neath and within the tonsil epithelium and dome epithelium of
Peyer patches. In contrast, no or a low number of IRTA1+ cells
was usually observed in the MZ of mesenteric lymph nodes and
spleen. Interestingly, monocytoid B cells in reactive lymph nodes
wre strongly positive. Further studies on MZLs are ongoing at
present with the same antibodies.
